Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07816341) titled 'Phase 1 Study of F182112 in Relapsed/Refractory Autoimmune Hemolytic Anemia' on Sept. 7.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Condition:
Autoimmune Hemolytic Anemia
Intervention:
Drug: F182112 single-agent
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: October 10, 2026
Target Sample Size: 12
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/study/NCT0...